ISRCTN10626053 https://doi.org/10.1186/ISRCTN10626053

Proteomics and pancreatic cystic neoplasms: a pilot study

Submission date	Recruitment status	[ ] Prospectively registered
03/06/2010	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
10/06/2010	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
10/06/2010	Digestive System	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Study website
http://www.unige.ch

Contact information

Type(s)
Scientific

Contact name
Prof Jean Louis Frossard

Contact details
Service of Gastroenterology
Dept of Internal Medicine
Rue Micheli du Crest
Geneva
Switzerland
1211

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
001

Study information

Scientific Title
Use of proteomics to differentiate between benign and potentially malignant pancreatic cystic neoplasms: a pilot study

Study objectives
We postulate that a proteomic analysis of pancreatic cystic fluid from patients having a pancreatic cystic neoplasms would be more performant than any other technique to discriminate between benign and malignant lesions.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethic Committee of Hirslanden Clinic (Surgery Section), Bern approved in March 2009

Study design
Prospective cohort proteomic analysis study

Primary study design
Observational

Secondary study design
Cohort study

Study setting(s)
Hospital

Study type(s)
Diagnostic

Participant information sheet
Not available in web format, please use contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Pancreatic disease

Interventions
Prospective collection of pancreatic cystic fluid in patients undergoing open pancreatic surgery aimed at removing the cystic neoplams. Cystic fluid samples collected by direct puncture and submitted to proteomic analysis.

Intervention Type
Other

Phase
Not Applicable

Primary outcome measure
To help find specific protein markers to better differentiate between benign and potentially malignant pancreatic cystic neoplams

Secondary outcome measures
To correlate results of the proteomic analysis to pancreatic histologic staining of surgical samples

Overall study start date
01/06/2009

Completion date
31/12/2010

Eligibility

Key inclusion criteria
1. Patients with pancreatic cystic neoplasms as demonstrated by CT scan planned for open surgery
2. Each patient gave his/her informed consent before surgery

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
10

Key exclusion criteria
1. Age < 18 years old
2. Pregnant women

Date of first enrolment
01/06/2009

Date of final enrolment
31/12/2010

Locations

Countries of recruitment
Switzerland

Study participating centre
Service of Gastroenterology
Geneva
Switzerland
1211

Sponsor information

Organisation
Geneva University Hospital (Switzerland)

Sponsor details
Rue Micheli Du Crest
Genève
Switzerland
1211
+41 (0)22 3729346
jean-louis.frossard@hcuge.ch

Sponsor type
Hospital/treatment centre

Website
http://www.hepatogastro.ch

ROR
https://ror.org/01m1pv723

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Geneva University Hospital (Switzerland)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration